Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management
Figure 6
Histopathologic analyses showing focal active colitis (a) with crypt destruction, loss of goblet cells, and neutrophilic infiltrates in the crypt epithelium (b) [13]; reproduced with permission from Maker et al. 2005 [13].
